Initial Seed Financing Secured August 21, 2007 • admin • Funding, Pharmaceuticals Following the incorporation of the company, Countervail was able to secure its initial seed funding from an Austrian pharmaceutical company that synthetically manufactures galantamine which is the company’s initial drug under development. Related News Countervail Corporation’s Pre-proposal Accepted by NINDS CounterACT October 7, 2016 Master License Agreement Signed with University of Maryland Baltimore for the use of galantamine as a treatment for organophosphate poisoning July 12, 2007